Escitalopram in the treatment of anxiety symptoms associated with depression
- 1 January 2006
- journal article
- research article
- Published by Hindawi Limited in Depression and Anxiety
- Vol. 24 (1), 53-61
- https://doi.org/10.1002/da.20141
Abstract
Most patients with depression have symptoms of anxiety associated with their illness. Our aim in this study was to investigate the efficacy of escitalopram, a proven antidepressant, on symptoms of anxiety in patients with major depressive disorder (MDD). Data from five placebo-controlled escitalopram studies in MDD were analyzed. Three of the studies also included a comparison with citalopram. In all studies, anxiety was assessed using the Inner Tension item (item 3) of the Montgomery-Asberg Depression Rating Scale (MADRS). In three studies, anxiety symptoms were also specifically assessed, either continuously over time or at baseline and end point, by using the Hamilton Rating Scale for Anxiety (HAM-A), the Anxious Mood item of the HAM-A (item 1), the Psychic Anxiety subscale of the HAM-A (items 1-6 and 14), the Anxiety Psychic item (item 10) of the Hamilton Rating Scale for Depression (HAM-D-24), and the Anxiety/Somatization subfactor (items 10-13, 15, and 17) of the HAM-D-24. Escitalopram was significantly superior to placebo in all comparisons. Citalopram was also consistently better than placebo in all comparisons, except in the HAM-D-24 Anxiety/Somatization subfactor. In some comparisons with placebo, escitalopram showed a significantly earlier onset of action or an earlier separation. Escitalopram was significantly more effective compared to placebo in treating both anxiety symptoms and the entire depression in the total depressive population, as well as in depressive patients with a high degree of anxiety.Keywords
This publication has 36 references indexed in Scilit:
- Treatment of generalized anxiety disorder with escitalopram: Pooled results from double-blind, placebo-controlled trialsJournal of Affective Disorders, 2005
- Escitalopram in the treatment of social anxiety disorderThe British Journal of Psychiatry, 2005
- Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose studyDepression and Anxiety, 2004
- Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptomsDepression and Anxiety, 2002
- Lifetime panic–depression comorbidity in the National Comorbidity SurveyThe British Journal of Psychiatry, 2000
- A Double-Blind, Multicenter Study in Primary Care Comparing Paroxetine and Clomipramine in Patients With Depression and Associated AnxietyPublished by Physicians Postgraduate Press, Inc ,1997
- The pharmacological effect of citalopram resides in the (S)-(+)-enantiomerJournal of Neural Transmission, 1992
- Major Depressive Disorder and Panic Disorder Effects of Comorbidity on Treatment Outcome with Antidepressant MedicationsClinical Neuropharmacology, 1988
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960